Clinical Trial

BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1/2, open-label, dose escalation and expansion study to assess the safety, pharmacokinetics, and preliminary efficacy of BC3195 in combination with pembrolizumab in participants with locally advanced or metastatic solid tumors.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-29
Trial Details
NCT Number NCT07469774
Lead Sponsor Biocity Biopharmaceutics Co., Ltd.
Collaborators: Merck Sharp & Dohme LLC
Conditions Locally Advanced or Metastatic Solid Tumors
Enrollment 111 participants
Start Date 2026-03-31
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-28